Member Info for George-Inn

So shall the negative trending of the share price. When the new quarter sets off, the MM's will look towards stability and news forward such as year end results & conference call for transition of CEO and potential clues to clinical trial progression and expected early results. This adjustment towards progression should stabilize the shares, and begin the crawl upward into summer and additional news on clinicals and transition of Craig's role. A new quarter brings new hope, buy low whilst you can. ....Cheers

Wonder what the short and long term position of the company will be as a result of this action. I believe that Jim has been a dedicated leader and certainly a good communicator on the media front. Dropping this on the mat today will set precedent for the shareholder call next month to go over the annual earnings, and then again at the annual meeting. Running this company has been somewhat of a challenge and no doubt requires an enormous amount of energy. I feel that the share price has reflected the markets attitude toward the expectations for profit and leadership, so DR. Cook will soon have the opportunity to prove himself, reverse the trend of the share price and deliver on the clinical trials. I've seen these changes in leadership before and one thing is for certain it will either get much better or much worse over time, but it will not continue on this course. I am hopeful that Craig has what it takes to succeed and turn this around in a dramatic fashion in a year or less. In the interim I continue to build my lot and add shares, let's see how the market digest this news.

Well I keep accumulating as I've stated several times, but it's not me snagging those large blocks. My pockets aren't that deep, but I've been buying in modest amounts for the past 12 - 18 months just accumulating a few thousand here and there each time to build a nice lot of shares. Up we must go even if we drift down to 25p we'll go up once the annuals are released and we have a conference call with updates.

grandadtom - I'd have to agree with your assessment and yes shaping up nicely on the news flow for 2018. One thing to add and expand upon early from Jim is the need to partner the MTD119 program in total. Like he said its a bit of an ask for MTPH to take on the task of the clinical trials alone. ODD opens the doors for financial bargaining and makes partnering more incentivized. Potential partners of the Liver collaboration are going to be looking at a clear path now with ODD and I suspect that MTD119 will become fairly focused going into 2019 with partner selection later this year. If a big partner is named for the clinical study then it could be possible that the partner may have more interest in the success of MTPH than one first thinks.

I'd suspect that there may be an opportunity to release a little fresh news either in conjunction with or prior to the planned reporting update in April. We shall see, I'm staying tuned, and adding more and see no reason not to. With the numbers shares to public being low this will pop-up hard.

Grandadtom - Agreed no real surprises, but they did stress the value inflection points are coming and seeing that as a major pop in share price. The term (confirmatory study results) is basically the same as value inflection. Once they prove that the product works in clinical trials, then they can begin to write their own ticket as the hard work now moves aside for scaled up manufacturing and prep to gain approval. April will be more details and I really don't expect much in the way of SP advancement until then. I also agree with LawrenceH that these next couple of months should be good time to top up and average in, as those "value inflection points" prove out and ultimately get announced. All good, and no surprises, unless they post some news about license rights or acquisition for a new product that fits in the wheelhouse and can begin immediately selling for increased revs. Otherwise we wait for April and get more updates and the expected value drivers come into play. Good Luck to all, I will be adding as usual.

LawrenceH - Spot on response. I've been an investor here for quite some time, and what we're investing in is as much in focus as why and how much. Jim and team have a very good pipeline, above average I'd say and revs from the states kick in hard 2018 plus opportunities. Once the interims on clinical trials are posted then the stock comes up on the radar. Expansion of current drug, coupled with sales increases and the fact they borrowed versus leveraging the shareholders, well this is all very telling. Investing and gambling are two very different animals, one required no thought and is pure luck. The other requires due diligence, review, study, timing and nose to the ground. I'm averaging down, and have been, I've said my terms on that and will continue building my lot.

Miss-Penny, I'd say that your assessment is spot on. News of annual earnings is due to drop at anytime, and if you recall Nick commented on the last Shareholder call that spend levels in H2 would be dramatically decreased and revenue reporting is going to be higher as well. Couple that with any additional positive news and you have the makings of a "substantive" SP increase. AIM is a tough market to tame and fair valuations are not always represented, but when you consider the pipeline, total revenues and yes sticky hands then the picture gets a little clearer for the serious investor here. I've said my place and commented that I continue to add at depressed levels as there really is only upside from here. I've added at every level and this cost averaging over time plays into my favor and my lot grows. I'm getting sticky hands myself, and stashing these shares for the future, as news looms.

LawrenceH I would venture to guess and based on past RNS release that Jim and the company will soon release some short brief with highlights of earnings and schedule of next call. I would agree with your comments as to the great news as well and would imagine that it is sufficient in detail and will propel the SP higher.

Looking for that unusual sign of an unexpected volume spike, increase in share price or combination of both. That's the sign that potentially points to information or news leak of either RNS or stateside of pending earnings. It's fairly common when you read the signs, and it shouldn't be long until a company brief comes out detailing the annual revenues, and results.

Based on all the news released thus far the share price still languishes a bit. We had a healthy pop although short lived on the financing news, thus providing a longer runway into 2019 and trials basically accounted for. But I recall a separate loan facility announced sometime last year that was for 8 million and wonder if payout from that could be triggered if a good deal presented itself. My thoughts are that is might be possible that management could conceivably be working on another license deal or product that could "boost sales" immediately. Something like that announced along with positive Y/E results and stateside now at breakeven well that kind of news could just be the ticket to much more stable S/P and let stateside sell more products that could be manufactured in-house. I for one wouldn't be surprised if the company weren't working on something in addition to the Y/E results, as this leadership team is packed with great minds and dedicated leaders, so I am curious as to what if anything they'll announce that might be possible additional news...waiting and watching.

Yes delivering on expectations and promises. That says a lot for the management team and leaders, lets hope for positive results on all clinical trials, and keeping fingers crossed for good results from full year and set a positive spin for stateside and revenues.

Next likely news is probably brief by Jim on year-end earnings. Curious to see if stateside the team is reaching the B/E point. Would like to see some surprise uplift in earnings or some milestone of B/E analysis. But likely that is next news, unless there's another clinical trial started.

Well personally I think the call of 5% is being a bit conservative for the longer picture. If the product is easier to mix and dose for clinicians and the effects are equal to SLAR, then the 5% will increase to a higher percentage as the full adoption takes off. Sure the increase may come over time, but even if its 5 years that's okay if its higher market percentage. Also I think I will wait for the 12-15 bagger then we're looking attractive to all with much improved revenues and potential opportunities increase. I'd also wager that management is looking to add another key revenue generating product to their current list. They have funds now from both the dilutive and non-dilutive and another cash generating product could be a positive as we await the clinical trial results.

Well thanks Colville, and let's see how the news flow goes in the coming days and weeks. I've been adding at those depressed share price levels for a long, long time. Really wasn't worried, and now seeing the start of what could be a great year for Midatech.

I'd say that with a bit of news early in the new year plus a trading update that this share price doubles Ina switch and then depending on the frequency and order of news it could then double yet again. These lean times may just well be the end of year selling and lack of news. My money is still on Jim and the team and Legal and Woodford seem to share that thought. Let's see what news comes now.

Well grandadtom, at this juncture I'd say one of several possibilities loom, but until the company release info on any of them the shareprice will likely continue to move down. I will list them in order of most likelihood. First I think that year end tax selling and positioning is current and will continue through this week. Why would the company release any good news about successful equity finance deal or any other major news if the year end selling takes center stage, these are actual occurrences. Next possibility is that a suitor is at hand and has made a bid for our company. There are a few like GSK and Novartis whom could seek a lucrative deal on the cheap if they got Woodford and others on board with the promise of turning a little profit earlier in the cycle also pure speculation. Or it could be possible that one or more of the senior management is jumping ship and moving on after end of year, pure speculation. Or it all could be nothing more then delayed news releases until the end of year and a bounty of news will come as they kick of the new year and report stellar H2 results. Again these are merely speculative but could point potentially to your closing sentence. Regardless these are indeed interesting times, and I continue to add on the low here 37p and hope that the pay drop for directors lit a fire and news is soon released. Fundamentally nothing has changed and the manufacturing should soon start along with clinical tests.

I agree with you missthepenny62. I read and re-read those areas of the RNS several times, and yet why we have a lull in news I continue to buy and add here. Further more convincing are the two main players (Woodford and Legal) as they sunk millions into this as capitalist investors, and also believe in the success of the upcoming programmes. You'll likely look back at your own decision not to sell, and hopefully you'll be rewarded with your actions. I personally am looking for major SP advancement over the next 12 - 18 months. My horizon though is a bit longer as I'd like to stay invested through the approval stages of all three current pipeline products.

Well GD-Tom I feel pretty certain that Jim and team will deliver on that guidance. The first step was to get the manufacturing piece certified for production of the needed component and formulation in which to produce sufficient amounts for the clinical tests. Over the next weeks and months I would suspect that much more news will come out as those crucial clinical trials spin up. I'm patient and continue to add to my positions. As always good luck and hope your strategy and investments work out to your favor.

Congrat's to Jim and team for reaching this important and much needed manufacturing milestone. This is truly a positive step and will increase the likelihood that manufacturing scale reaches it intended target and that soon we'll get a bit of good news related to the equity raise to ensure adequate funding is secured for the longer path to clinical results and approvals. That will truly be pivotal and when secured should add a much needed boost to the share price. Good luck to all and I will continue to keep adding periodically to my position as I believe in this small but driven company and their leadership.